Your browser doesn't support javascript.
loading
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.
Akkaif, Mohammed Ahmed; Sha'aban, Abubakar; Cesaro, Arturo; Jaber, Ammar Ali Saleh; Vergara, Andrea; Yunusa, Ismaeel; Jatau, Abubakar Ibrahim; Mohammed, Mustapha; Govindasamy, G Saravana; Al-Mansoub, Majed Ahmed; Sheikh Abdul Kader, Muhamad Ali; Ibrahim, Baharudin.
Afiliação
  • Akkaif MA; School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Penang, Malaysia.
  • Sha'aban A; School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Penang, Malaysia. abuushaaban2@gmail.com.
  • Cesaro A; Department of Cardio-Thoracic and Respiratory Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Jaber AAS; Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai Pharmacy College for Girls, 19099, Dubai, United Arab Emirates.
  • Vergara A; Department of Cardio-Thoracic and Respiratory Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Yunusa I; College of Pharmacy, University of South Carolina, Columbia, United States.
  • Jatau AI; School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Tasmania, Australia.
  • Mohammed M; School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Penang, Malaysia.
  • Govindasamy GS; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Kaduna, Nigeria.
  • Al-Mansoub MA; School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Penang, Malaysia.
  • Sheikh Abdul Kader MA; Centre for Drug Research, Universiti Sains Malaysia, 11800, Penang, Malaysia.
  • Ibrahim B; Department of Cardiology, Penang General Hospital, 10990, Penang, Malaysia.
Inflammopharmacology ; 30(4): 1143-1151, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35701719
ABSTRACT
The coronavirus disease-2019 (COVID-19) pandemic has become a major global health problem. COVID-19 is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and exhibits pulmonary and extrapulmonary effects, including cardiovascular involvement. There are several attempts to identify drugs that could treat COVID-19. Moreover, many patients infected with COVID-19 have underlying diseases, particularly cardiovascular diseases. These patients are more likely to develop severe illnesses and would require optimized treatment strategies. The current study gathered information from various databases, including relevant studies, reviews, trials, or meta-analyses until April 2022 to identify the impact of SARS-CoV-2 treatment on the cardiovascular system. Studies have shown that the prognosis of patients with underlying cardiovascular disease is worsened by COVID-19, with some COVID-19 medications interfering with the cardiovascular system. The COVID-19 treatment strategy should consider many factors and parameters to avoid medication-induced cardiac injury, mainly in elderly patients. Therefore, this article provides a synthesis of evidence on the impact of different COVID-19 medications on the cardiovascular system and related disease conditions.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Sistema Cardiovascular / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Sistema Cardiovascular / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article